ProMIS Neurosciences (PMN) Capital Expenditures (2021 - 2022)
ProMIS Neurosciences' (PMN) quarterly Capital Expenditures came in at -$43.0 in Q4 2022, down 100.89% YoY from $4857.0 in Q4 2021, and down 79.17% on a QoQ basis from -$24.0 in Q3 2022.
ProMIS Neurosciences (PMN) Capital Expenditures (2021 - 2022) Analysis & Trends
ProMIS Neurosciences (PMN) has 2 years of Capital Expenditures data on file, last reported at -$43.0 in Q4 2022.
- Quarterly Capital Expenditures fell 100.89% year-over-year to -$43.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1981.0 (changed N/A YoY) and the FY2022 annual result came in at $1981.0, down 67.22% from the prior year.
- Capital Expenditures eased to -$43.0 in Q4 2022, from -$24.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $4857.0 in Q4 2021 to a low of -$43.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 251.02 Mn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -43.00 |
| Dec 31, 2022 | -43.00 |
| Sep 30, 2022 | -24.00 |
| Sep 30, 2022 | -24.00 |
| Jun 30, 2022 | -9.00 |
| Jun 30, 2022 | -9.00 |
| Mar 31, 2022 | 2,057.00 |
| Mar 31, 2022 | 2,057.00 |
| Dec 31, 2021 | 4,857.00 |
| Dec 31, 2021 | 4,857.00 |